Axitinib in combination with radiotherapy for advanced hepatocellular carcinoma: a phase I clinical trial

BACKGROUND: To investigate maximum tolerated dose (MTD) of axitinib, a selective vascular endothelial growth factor receptor 1–3 inhibitor, in combination with radiotherapy (RT) for advanced hepatocellular carcinoma (HCC). METHODS: This phase I study followed the rule of traditional 3 + 3 design. Ma...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Kai-Lin, Chi, Mau-Shin, Ko, Hui-Ling, Huang, Yi-Ying, Huang, Su-Chen, Lin, Yu-Min, Chi, Kwan-Hwa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7819176/
https://www.ncbi.nlm.nih.gov/pubmed/33472666
http://dx.doi.org/10.1186/s13014-020-01742-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7819176/
https://www.ncbi.nlm.nih.gov/pubmed/33472666
http://dx.doi.org/10.1186/s13014-020-01742-w

Ejemplares similares